The physics of atoms and the technology behind treating disease might sound like disparate fields. However, in the past few decades, advances in artificial intelligence, sensing, simulation and more have driven enormous impacts within the biotech industry.
A new study by the IBM Institute for Business Value found that surveyed CEOs are facing workforce, culture and governance challenges as they act quickly to implement and scale generative AI across their organizations.
Tech Mahindra, a leading global provider of technology consulting and digital solutions to enterprises across industries, announced they are collaborating with IBM (NYSE: IBM) to help businesses worldwide responsibly accelerate the adoption of generative AI (GenAI). TechM amplifAI0->∞, Tech Mahindra’s suite of AI offerings and solutions, can integrate with the IBM watsonx AI and data platform with AI Assistants to bring new GenAI and governance capabilities to enterprises.
The following email was sent to all IBMers: I am writing to share some important news about our Consulting leadership team and how we are positioning ourselves for the next phase of growth. After...
Tech Mahindra and IBM to Help Enterprises Accelerate Adoption of Trustworthy Generative AI Using watsonx